• R&D

Chosen for the New Energy and Industrial Technology Development Organization (NEDO) Deep Tech Startup Support Project (DTSU)

• Celaid Therapeutics Inc. with its CEO, Nobuyuki Arakawa, is pleased to announce today that it has been selected in the third round of applications for the fiscal year 2023 Deep Tech Startup Support Program (DTSU) conducted by the New Energy and Industrial Technology Development Organization (NEDO). The University of Tokyo Edge Capital Partners (UTEC) will be the VC partner for the STS phase of the project.

• With this support, Celaid aims to apply its hematopoietic stem cell (HSC) expansion technology to therapies alleviating patients worldwide who suffer from blood and genetic diseases.


Development of HSC Expansion Platform Technology for Cell and Gene Therapy Products
As part of this project, Celaid will establish and validate systems for supplying clinical and commercial-grade HSC expansion methods and culture media to the biotechnology field enabling companies to address technical challenges encountered in commercial manufacturing of cell and gene therapy products.

Since its founding in October 2020, Celaid Therapeutics Inc. has been engaged in research and development of ex vivo HSC expansion technology targeting the US market from early stage to commercialization. Celaid has participated in multiple accelerator programs to date and formed collaborative research relationships with domestic and overseas academic institutes and companies. Over this period, we have discovered that our human HSC expansion technology can provide solutions to several technical challenges faced in the cell and gene therapy field. Having been selected for the NEDO project, Celaid aims to further improve its core technologies for clinical and commercial manufacturing, easing the integration of our HSC expansion technology into cell and gene therapy programs around the globe.


About Celaid Therapeutics Inc.
Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products in cell therapy for hematologic disease and ex vivo HSC gene therapy for genetic disorders.

Contact Information
Celaid Therapeutics Inc.
Address:Utokyo Entrepreneur Lab., South Clinical Research Bldg., 7-3-1 Hongo,Bunkyo-ku, Tokyo 113-8485, Japan

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2024 All Rights Reserved Powered by STINGER.